NCT05207371 is a Phase 1, PHASE2 clinical trial of Biological in Cell Therapy, sponsored by GAIA BioMedicine Inc..

Who is sponsoring NCT05207371?

NCT05207371 is sponsored by GAIA BioMedicine Inc..

What drugs are being tested in NCT05207371?

Interventions in NCT05207371: Biological.

What condition does NCT05207371 study?

NCT05207371 studies Cell Therapy, NSCLC.

Is NCT05207371 still recruiting?

NCT05207371 is currently status unknown. Last updated 26 January 2022.

Last reviewed 2022-01-26 · How we verify

NCT05207371

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

Status unknown Phase 1, PHASE2 Last updated 26 January 2022

What this trial tests

Phase 1, PHASE2 trial testing Biological in Cell Therapy in 38 participants. Status unknown.

Timeline

1 December 2021

Primary endpoint
1 October 2022

1 December 2025

Quick facts

Lead sponsor	GAIA BioMedicine Inc.
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	1 December 2021
Primary completion	1 October 2022
Estimated completion	1 December 2025
Sites	3 locations across Japan

Drugs / interventions tested

Biological — full drug profile →

Conditions studied

Cell Therapy — all drugs for Cell Therapy →
NSCLC — all drugs for NSCLC →

Sponsor

GAIA BioMedicine Inc. — full company profile →

Who can join

20 and older, any sex, with Cell Therapy or NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I Part : Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II. Phase II Part : Explore the efficacy and safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer at the recommended dose of GAIA-102 decided in the Phase I part.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Li MSC, Mok KKS, Mok TSK. · · 2023 · cited 37× · PMID 37675321 · DOI 10.21037/atm-22-4444
Novel NK cell-like phenotype expressing CCR5 and its ligands elicits tumor-specific acquired immunity to carcinomatous peritonitis via host NK-derived IFN-γ.
Zheng S, Harada Y, Morodomi Y, Yasuda N, et al · · 2026 · PMID 42009357 · DOI 10.1136/jitc-2025-014300

Verify or expand the search:

Other trials of Biological

Trials testing the same drug.

NCT06444503 — Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies · recruiting
NCT05893693 — Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia · NA · unknown
NCT05608148 — Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors · Phase 1 · recruiting
NCT04542967 — Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease · Phase 2 · completed
NCT03327493 — Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO · NA · completed

Other recruiting trials for Cell Therapy

Currently open trials in the same condition.

NCT06839976 — CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus · Phase 1, PHASE2 · recruiting
NCT06575374 — Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell · Phase 2 · recruiting
NCT07183384 — MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction · Phase 1, PHASE2 · recruiting
NCT06643221 — Exercise as an Immune Adjuvant for Allogeneic Cell Therapies · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05207371 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GAIA BioMedicine Inc.
Last refreshed: 26 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing